Pfizer Vaccine May Offer Strong Protection after First Dose, Israeli Study Shows
Click the image below to enlarge the infographic.
- A new Israeli study of vaccinated healthcare workers at the country's largest hospital has found that the COVID-19 vaccine developed by Pfizer and BioNTech produces a robust immune response after the first dose
- The research, published in the medical journal Lancet, followed 7,214 staff members at Sheba Medical Center, who received the first dose of the Pfizer-BioNTech vaccine between Dec. 19 and Jan. 24
- Researchers at the center found that the vaccine was 85 percent effective at preventing symptomatic COVID-19 infection within 15 to 28 days after administration
- The study also found a 75 percent reduction in both symptomatic and asymptomatic infections after the first shot of the vaccine
- However, experts warn that more evidence may be needed before broad conclusions can be drawn